Correlation Between AnaptysBio and Acrivon Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both AnaptysBio and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AnaptysBio and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between AnaptysBio and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on AnaptysBio and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AnaptysBio with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of AnaptysBio and Acrivon Therapeutics,.

Diversification Opportunities for AnaptysBio and Acrivon Therapeutics,

-0.39
  Correlation Coefficient

Very good diversification

The 3 months correlation between AnaptysBio and Acrivon is -0.39. Overlapping area represents the amount of risk that can be diversified away by holding AnaptysBio and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and AnaptysBio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AnaptysBio are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of AnaptysBio i.e., AnaptysBio and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between AnaptysBio and Acrivon Therapeutics,

Given the investment horizon of 90 days AnaptysBio is expected to generate 0.75 times more return on investment than Acrivon Therapeutics,. However, AnaptysBio is 1.33 times less risky than Acrivon Therapeutics,. It trades about 0.12 of its potential returns per unit of risk. Acrivon Therapeutics, Common is currently generating about -0.11 per unit of risk. If you would invest  1,322  in AnaptysBio on December 30, 2024 and sell it today you would earn a total of  573.00  from holding AnaptysBio or generate 43.34% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

AnaptysBio  vs.  Acrivon Therapeutics, Common

 Performance 
       Timeline  
AnaptysBio 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in AnaptysBio are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, AnaptysBio sustained solid returns over the last few months and may actually be approaching a breakup point.
Acrivon Therapeutics, 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

AnaptysBio and Acrivon Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with AnaptysBio and Acrivon Therapeutics,

The main advantage of trading using opposite AnaptysBio and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AnaptysBio position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.
The idea behind AnaptysBio and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets